Feb 11 (Reuters) – Abbvie sued the U.S. Department of Health and Human Services on Wednesday, challenging a decision by the Centers for Medicare & Medicaid Services to select Botox for prescription drug price controls established by the federal Inflation Reduction Act of 2022.
The lawsuit was filed in the Washington, D.C. federal court. It also names CMS and its administrator Mehmet Oz as defendants.
(Reporting by Jonathan Stempel in New York)
